← Back to Search

Radiopharmaceutical

131I-MIP-1095 for Prostate Cancer

Phase 1
Waitlist Available
Led By Michael Morris, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Summary

The main purpose of this study to determine the safety of an experimental medicine called 131I-MIP-1095. 131I-MIP-1095 is an investigational drug, meaning it has not been approved by the U.S. Food & Drug Administration (FDA).

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum Tolerated Dose (MTD)

Trial Design

1Treatment groups
Experimental Treatment
Group I: 131I-MIP-1095Experimental Treatment1 Intervention
FirstTherapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose. 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MIP-1095 I-131
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Progenics Pharmaceuticals, Inc.Industry Sponsor
33 Previous Clinical Trials
4,348 Total Patients Enrolled
17 Trials studying Prostate Cancer
1,782 Patients Enrolled for Prostate Cancer
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,944 Previous Clinical Trials
589,741 Total Patients Enrolled
133 Trials studying Prostate Cancer
51,580 Patients Enrolled for Prostate Cancer
Michael Morris, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
15 Previous Clinical Trials
2,859 Total Patients Enrolled
11 Trials studying Prostate Cancer
930 Patients Enrolled for Prostate Cancer
~1 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top